ArticleComprehensive psychoneuroendocrinology2025
Sleep disturbances linked to plasma orexin A levels in patients with bipolar disorder: A preliminary study.
Article in Comprehensive psychoneuroendocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sleep disturbances are a core symptom of bipolar disorder (BD). Other sleep disturbances such as nightmares, sleep apnea and restless legs are also common in BD. Biomarkers related to the sleep-wake cycle, specifically orexins, have attracted research on their role in other psychiatric disorders, but have been less explored in BD. We aimed to analyze the relationship between orexin A levels and sleep characteristics in patients with BD. This is a secondary analysis of a cross-sectional study including 113 outpatients during follow-up. The Oviedo Sleep Questionnaire was used to evaluate sleep characteristics. The Hamilton Depression Rating Scale, the Young Mania Rating Scale, and the Hamilton Anxiety Rating Scale were used to assess clinical status. Orexin A, Interleukin 1 receptor antagonist, and tumor necrosis factor alpha were measured in plasma. Sociodemographic and other clinical variables were collected. Statistical analysis using parametric tests and logistic regression were performed. No differences between sexes (62 % women) were found for any sleep disturbances. Snoring, restless legs, and nightmares, but not insomnia, showed an association with orexin A. In logistic regression models, restless legs were associated with severity of depression (OR: 1.070, p = 0.015), Interleukin 1 receptor antagonist (OR: 1.004, p = 0.037), and orexin A (OR: 0.963, p = 0.022). As for nightmares, only severity of anxiety (OR: 1.113, p < 0.001), and benzodiazepines (OR: 0.166, p = 0.006) showed an association. This is one of the few studies analyzing the relationship of sleep quality and orexin A in BD. Evaluating sleep disturbances other than insomnia in BD is valuable, since they are often associated with worse clinical outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.